HBIO - ハ―バ―ド・バイオサイエンス （Harvard Bioscience Inc.）

The following slide deck was published by Harvard Bioscience, Inc.

Harvard Bioscience, Inc. (NASDAQ:NASDAQ:HBIO) Q3 2022 Earnings Conference Call November 08, 2022, 16:30 ET Company Participants David Sirois - Director, Corporate Accounting & SEC…

Harvard Bioscience press release (HBIO): Q3 Non-GAAP EPS of -$0.01.Revenue of $76.9M.“Looking to the future, we expect to complete our portfolio optimization and related cost actions…

“Fighting through challenging times while building the company and new technologies for the future.” “Fighting through challenging times while building the company and new technologies for the future.”

Harvard Bioscience (NASDAQ: HBIO ) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here''s what investors need to know before the announcement. Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.07. Harvard Bioscience bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

Harvard Bioscience announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the consensus…

The following slide deck was published by Harvard Bioscience, Inc.

Harvard Bioscience, Inc. (NASDAQ:NASDAQ:HBIO) Q1 2022 Earnings Conference Call May 4, 2022 08:00 ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting…

Harvard Bioscience press release (NASDAQ:HBIO): Q1 Non-GAAP EPS of $0.04 misses by $0.02.Revenue of $28.78M (+6.6% Y/Y) beats by $0.05M.

HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022.

Strs Ohio cut its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 7.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 97,400 shares of the medical instruments suppliers stock after selling 8,100 shares during the quarter. Strs Ohios holdings in Harvard Bioscience were worth $679,000 at the end of the most recent reporting period. []

Wells Fargo & Company MN raised its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 71.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 423,186 shares of the medical instruments suppliers stock after acquiring an additional 176,253 shares during the quarter. Wells Fargo & Company MNs holdings in Harvard Bioscience were worth $3,525,000 as []

Analysts predict that Harvard Bioscience, Inc. (NASDAQ:HBIO) will report sales of $32.65 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Harvard Biosciences earnings, with the lowest sales estimate coming in at $32.50 million and the highest estimate coming in at $32.80 million. Harvard Bioscience reported sales of $30.98 million []

Millennium Management LLC lifted its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 144.6% during the second quarter, Holdings Channel.com reports. The firm owned 145,562 shares of the medical instruments suppliers stock after acquiring an additional 86,058 shares during the period. Millennium Management LLCs holdings in Harvard Bioscience were worth $1,213,000 as of its []

Prudential Financial Inc. purchased a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,509 shares of the medical instruments suppliers stock, valued at approximately $113,000. Several other hedge funds and other institutional []